FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CH	ANGES
SIAILMLINI	OF CIT	TINGES

IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Thomsen Jillian B.						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [NKTR]									c all applic Directo	able)	g Person(s) to Is 10% (Other		
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH						3. Date of Earliest Transaction (Month/Day/Year) 11/11/2015								X Officer (give title Other (specify below) SVP & Chief Accounting Officer					
(Street) SAN FRANC	isco C	A	94158		4. 1	If Ame	endme	nt, Date	e of Original Filed (Month/Day/Year)					6. Indi Line) X	•				
(City)	(S	tate)	(Zip)																
		Tab	le I - No	n-Deri\	vativ	e Se	curit	ties Ac	quired	, Dis	sposed o	f, or Be	nefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			y/Year) Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4)				and 5) Securities Beneficion		es ally Following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
						Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3	ction(s)			(Instr. 4)			
Common Stock ⁽¹⁾ 11/11/2					/2015	М		15,000	A	\$6.	6.65 18,		,499		D				
Common Stock ⁽¹⁾ 11/11/2			/2015	2015		S		15,000	D	\$13.	52 ⁽²⁾	3,499			D				
		-	Table II -								osed of, converti				wned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Execution Da		Date, Transact Code (In:				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
				Co	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Number of Shares	er					
Stock Option ⁽¹⁾	\$6.65	11/11/2015			M			15,000	03/20/20)12	03/19/2016	Common Stock	15,00	00	\$0.00	60,000		D	

Explanation of Responses:

- 1. This transaction was made pursuant to a Rule 10b5-1 trading plan for stock options scheduled to expire in early 2016 as described in the Current Report on Form 8-K filed by Nektar Therapeutics on July 16,
- 2. This transaction was executed in multiple trades at prices ranging from \$13.18 to \$13.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Remarks:

Gil M. Labrucherie, Attorneyin-Fact

11/13/2015

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.